# INSIGHT 2 (NCT03940703)

> A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

No report yet. It can be ordered.

- Indication: advanced EGFR-mutated MET-amplified NSCLC following first-line osimertinib progression

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03940703
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: EMD Serono Research & Development Institute, Inc.
- Conditions: Non-small Cell Lung Cancer
- Interventions: Tepotinib; Osimertinib
- Enrollment: 140
- Primary outcome: Combined Therapy (Tepotinib+Osimertinib): Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version (NCI-CTCAE v 5.0)
- Primary outcome: Combined Therapy: Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by Fluorescence in Situ Hybridization(FISH)

## Indexed commentary on INSIGHT 2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 30 posts on X
- 22 podcast episodes
- 11 YouTube videos

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=insight-2-nct03940703

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03940703", "email": "<work email>"}; the inbox owner confirms by the emailed link.